TELA Bio Exceeds Q1 Guidance with $19M Revenue, Names Four New Board Members
TELA•TELA Bio reported preliminary first-quarter 2026 revenue of $19.0 million, surpassing its guidance of $18.5 million. The board will replace four outgoing directors with four seasoned executives in medtech commercialization, venture capital and turnarounds following the June 9 annual meeting to drive operational efficiency and profitability.
1. Board Refresh to Enhance Commercial and Financial Expertise
In a unanimous decision at its June 9 annual meeting, TELA Bio will replace directors Doug Evans, Kurt Azarbarzin, Vince Burgess and Federica O’Brien with Joseph Capper, Guy Nohra, Joseph Neels and Paul Thomas. The incoming directors bring decades of medtech commercialization, venture capital investment and corporate turnaround experience, while Antony Koblish remains on the board.
2. Preliminary Q1 2026 Revenue Exceeds Guidance
TELA Bio reported preliminary revenue of $19.0 million for the first quarter of 2026 versus its prior guidance of $18.5 million. Full financial results will be released after the market close on May 12, 2026, and the preliminary figures may be adjusted upon completion of quarterly review and closing procedures.
3. Strategic Focus on Profitability and Operational Efficiency
The board refresh aligns with TELA Bio’s strategy to scale commercial operations, optimize cost structure and advance toward sustainable profitability. The new directors’ deep expertise in scaling medtech organizations and executing financial turnarounds is expected to accelerate value creation for shareholders.
